NewAmsterdam Pharma (NAMS) Competitors

NewAmsterdam Pharma (NASDAQ:NAMS) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Do analysts recommend NAMS or QGEN?

NewAmsterdam Pharma presently has a consensus price target of $41.20, suggesting a potential upside of 64.80%. Qiagen has a consensus price target of $49.69, suggesting a potential downside of 0.06%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Qiagen	0 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.27

Which has preferable earnings & valuation, NAMS or QGEN?

Qiagen has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$45.56M	61.80	-$241.60M	-$1.62	-15.43
Qiagen	$1.98B	5.59	$83.59M	$1.69	29.42

Is NAMS or QGEN more profitable?

Qiagen has a net margin of 18.30% compared to NewAmsterdam Pharma's net margin of -259.07%. Qiagen's return on equity of 14.77% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-259.07%	-27.27%	-25.00%
Qiagen	18.30%	14.77%	8.87%

Do insiders & institutionals have more ownership in NAMS or QGEN?

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 20.8% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the media refer more to NAMS or QGEN?

In the previous week, Qiagen had 8 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 11 mentions for Qiagen and 3 mentions for NewAmsterdam Pharma. Qiagen's average media sentiment score of 1.35 beat NewAmsterdam Pharma's score of 0.71 indicating that Qiagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, NAMS or QGEN?

NewAmsterdam Pharma has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Summary

Qiagen beats NewAmsterdam Pharma on 10 of the 16 factors compared between the two stocks.